Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements

Kriya Therapeutics, a gene therapy biotech company founded by Shankar Ramaswamy, has raised $313 million in its latest funding round5.

This significant capital infusion aims to drive the company's development of gene therapies and expand its clinical pipeline5.

The new financing adds to Kriya's prior fundraising, which now totals over $450 million since its founding in 201913.

The investment underscores rapid growth within the gene therapy sector, where Kriya has emerged as a leading player1.

Kriya is focused on developing treatments for multiple disease areas using its proprietary gene therapy platforms5.

Sources:

1. https://www.seedtable.com/best-gene-therapy-startups

3. https://www.bioprocessintl.com/therapeutic-class/kriya-bags-another-150m-funding-to-explore-gene-therapies

5. https://www.fiercebiotech.com/biotech/shankar-ramaswamys-gene-therapy-biotech-raises-313m